RA
IMPV

Royce & Associates’s Imperva, Inc. IMPV Stock Holding History

Royce & Associates’s Portfolio IMPV Stock Details IMPV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-105,000
Closed -$5.64M – 1122
2016
Q3 		$5.64M Buy
105,000
+15,000
+17% +$696K 0.04% 555
2016
Q2 		$3.87M Buy
+90,000
New +$3.78M 0.03% 665

Other funds holding IMPV

EM
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
EC
Eminence Capital New York $4.36B AUM 3.1% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
PCM
Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LM
Litespeed Management New York $48.2M AUM 9.81% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Royce & Associates's IMPV Position: Q4 2016 in Review

Royce & Associates sold out of Imperva, Inc. (IMPV) in Q4 2016, closing a stake of 105,000 shares — an estimated $5.64M sold.

Royce & Associates first reported a position in IMPV in Q2 2016 and held it in 2 quarters. The position peaked at $5.64M in Q3 2016. 172 funds tracked by Wall St. Rank hold IMPV as of Q4 2016.

  • Royce & Associates reported no remaining Imperva, Inc. position as of Q4 2016 after selling out during the quarter.
  • Royce & Associates sold 105,000 Imperva, Inc. shares in Q4 2016, an estimated $5.64M.
  • Royce & Associates first reported a position in Imperva, Inc. in Q2 2016 and held it in 2 quarters.
  • Royce & Associates's Imperva, Inc. position peaked at $5.64M in Q3 2016.
  • 172 funds tracked by Wall St. Rank held Imperva, Inc. as of Q4 2016.

Based on Royce & Associates's 13F filing for Q4 2016, filed 10 Feb 2017.